Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Bispecific Antibodies in Colorectal Cancer Therapy: Recent Insights and Emerging Concepts Publisher Pubmed



Ghalamfarsa F1 ; Khatami SH2 ; Vakili O3 ; Taherianganeh M1 ; Tajbakhsh A4 ; Savardashtaki A1 ; Fazli Y5 ; Uonaki LR6 ; Shabaninejad Z4, 7 ; Movahedpour A1, 8 ; Ghalamfarsa G9
Authors

Source: Immunotherapy Published:2021


Abstract

Colorectal cancer (CRC) is identified as a life-threatening malignancy. Despite several efforts and proceedings available for CRC therapy, it is still a health concern. Among a vast array of novel therapeutic procedures, employing bispecific antibodies (BsAbs) is currently considered to be a promising approach for cancer therapy. BsAbs, as a large family of molecules designed to realize two distinct epitopes or antigens, can be beneficial microgadgets to target the tumor-associated antigen pairs. On the other hand, applying the immune system's capabilities to attack malignant cells has been proven as a tremendous development in cancer therapeutic projects. The current study has attempted to overview some of the approved BsAbs in CRC therapy and those under clinical trials. For this purpose, reputable scientific search engines and databases, such as PubMed, ScienceDirect, Google Scholar, Scopus, etc., were explored using the keywords bispecific antibodies', colorectal cancer', immunotherapy' and tumor markers'. © 2021 Future Medicine Ltd.
Other Related Docs
13. Advanced Technologies for Cancer Immunotherapy: Focus on Gastrointestinal Cancers, Anti-Cancer Agents in Medicinal Chemistry (2025)
15. Ret Protein Expression in Colorectal Cancer; an Immunohistochemical Assessment, Asian Pacific Journal of Cancer Prevention (2021)
16. Recent Progress in Cancer Immunotherapy: Application of Nano-Therapeutic Systems, Journal of Drug Delivery Science and Technology (2024)